Insider Purchase Signal: Social media chatter has centered on a director's substantial acquisition of nearly $25 million in shares, marking the second major personal investment in recent months and underscoring confidence in the firm's clinical pipeline.
Pipeline Momentum: Participants noted the company's position on biotech catalyst lists for upcoming Phase 3 data in bladder cancer immunotherapy, with some highlighting potential for meaningful efficacy thresholds amid limited approved options.
Market Context: Discussions emphasized the scale of the commitment relative to compensation levels, positioning it as a notable indicator of internal optimism around regulatory pathways and combination therapy prospects.
Note: This discussion summary was generated from an AI condensation of post data.
CG Oncology Insider Trading Activity
CG Oncology insiders have traded $CGON stock on the open market 8 times in the past 6 months. Of those trades, 1 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $CGON stock by insiders over the last 6 months:
- BRIAN GUAN-CHYUN LIU purchased 371,085 shares for an estimated $24,814,453
- JAMES MULAY has made 0 purchases and 5 sales selling 28,709 shares for an estimated $1,841,830.
- LEONARD E POST has made 0 purchases and 2 sales selling 10,000 shares for an estimated $675,000.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
EARLY ACCESS
Receive CGON Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
CG Oncology Hedge Fund Activity
We have seen 123 institutional investors add shares of CG Oncology stock to their portfolio, and 74 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP added 4,972,681 shares (+247.1%) to their portfolio in Q1 2026, for an estimated $336,551,050
- DRIEHAUS CAPITAL MANAGEMENT LLC added 999,623 shares (+inf%) to their portfolio in Q1 2026, for an estimated $67,654,484
- PICTET ASSET MANAGEMENT HOLDING SA removed 951,522 shares (-70.5%) from their portfolio in Q1 2026, for an estimated $64,399,008
- KYNAM CAPITAL MANAGEMENT, LP removed 945,830 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $64,013,774
- FARALLON CAPITAL MANAGEMENT LLC added 666,000 shares (+8325.0%) to their portfolio in Q1 2026, for an estimated $45,074,880
- WELLINGTON MANAGEMENT GROUP LLP removed 628,558 shares (-10.5%) from their portfolio in Q1 2026, for an estimated $42,540,805
- UBS GROUP AG removed 611,768 shares (-31.8%) from their portfolio in Q1 2026, for an estimated $41,404,458
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
CG Oncology Price Targets
Multiple analysts have issued price targets for $CGON recently. We have seen 6 analysts offer price targets for $CGON in the last 6 months, with a median target of $81.5.
Here are some recent targets:
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $100.0 on 05/18/2026
- Gregory Renza from Truist Securities set a target price of $82.0 on 05/14/2026
- Yun Zhong from Wedbush set a target price of $80.0 on 05/11/2026
- Leonid Timashev from RBC Capital set a target price of $81.0 on 05/11/2026
- Brian Cheng from JP Morgan set a target price of $96.0 on 05/11/2026
- Kelsey Goodwin from Piper Sandler set a target price of $70.0 on 01/16/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
CG Oncology Stock (CGON) Opinions on Director's Massive Share Purchase
Insider Purchase Signal: Social media chatter has centered on a director's substantial acquisition of nearly $25 million in shares, marking the second major personal investment in recent months and underscoring confidence in the firm's clinical pipeline.
Pipeline Momentum: Participants noted the company's position on biotech catalyst lists for upcoming Phase 3 data in bladder cancer immunotherapy, with some highlighting potential for meaningful efficacy thresholds amid limited approved options.
Market Context: Discussions emphasized the scale of the commitment relative to compensation levels, positioning it as a notable indicator of internal optimism around regulatory pathways and combination therapy prospects.
Note: This discussion summary was generated from an AI condensation of post data.
CG Oncology Insider Trading Activity
CG Oncology insiders have traded $CGON stock on the open market 8 times in the past 6 months. Of those trades, 1 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $CGON stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
CG Oncology Hedge Fund Activity
We have seen 123 institutional investors add shares of CG Oncology stock to their portfolio, and 74 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
CG Oncology Price Targets
Multiple analysts have issued price targets for $CGON recently. We have seen 6 analysts offer price targets for $CGON in the last 6 months, with a median target of $81.5.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »